Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) EBT Margin (2016 - 2025)

Sonoma Pharmaceuticals has reported EBT Margin over the past 16 years, most recently at 21.82% for Q4 2025.

  • For Q4 2025, EBT Margin rose 396.0% year-over-year to 21.82%; the TTM value through Dec 2025 reached 19.47%, up 728.0%, while the annual FY2025 figure was 20.35%, 1916.0% up from the prior year.
  • EBT Margin for Q4 2025 was 21.82% at Sonoma Pharmaceuticals, down from 13.04% in the prior quarter.
  • Over five years, EBT Margin peaked at 2.54% in Q3 2021 and troughed at 142.82% in Q1 2022.
  • A 5-year average of 40.4% and a median of 29.61% in 2023 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: tumbled -5397bps in 2021 and later surged 9508bps in 2023.
  • Year by year, EBT Margin stood at 32.53% in 2021, then crashed by -99bps to 64.71% in 2022, then surged by 55bps to 29.41% in 2023, then rose by 12bps to 25.79% in 2024, then increased by 15bps to 21.82% in 2025.
  • Business Quant data shows EBT Margin for SNOA at 21.82% in Q4 2025, 13.04% in Q3 2025, and 30.93% in Q2 2025.